An observational, retrospective, case series assessing efficacy and safety of Denosumab plus Biologic DMARDs in patients with rheumatic chronic diseases.
Latest Information Update: 17 Aug 2016
Price :
$35 *
At a glance
- Drugs Denosumab (Primary)
- Indications Osteoporosis; Rheumatic disorders; Rheumatoid arthritis
- Focus Adverse reactions; Therapeutic Use
- 17 Aug 2016 New trial record